Nilai Buku saben Saham: Cyclacel (CYCC)

The bps metric reflects the dynamics of net assets per share, with the value currently standing at 2.28. The Cyclacel Pharmaceuticals (CYCC) team brings together leading cancer biologists dedicated to the study of cell cycles. Transparent management effectively allocates the R&D budget. Strong patent positions regarding inhibitors provide a robust defense, although early-stage trials maintain high volatility.

CYCC - Nilai Buku Siji Saham Cyclacel Pharmaceuticals, Inc. ing rentang 04.07.2022 - 12.09.2025

Ringkesan rincian data analitis cyclacel.com (CYCC)

- rega lan prakiraan konsensus rega:

Rega saham Cyclacel Pharmaceuticals Inc.|CYCC - Target konsensus

- data kapitalisasi pasar:

Kapitalisasi pasar Cyclacel Pharmaceuticals|CYCC - Rega Nyata Tumbas Perusahaan Kanthi Wutuh

- data kapitalisasi buku:

Nilai Buku saben Saham Cyclacel|CYCC - Nilai Buku Bisnis|Rasio Kapitalisasi Pasar marang Nilai Buku cyclacel.com|CYCC - Aset Perusahaan

- data utang lan likuiditas:

Utang marang Ekuitas Cyclacel Pharmaceuticals|CYCC - Rasio utang jangka dawa marang modal|Utang jangka cendhak marang modal Cyclacel|CYCC - Utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku Cyclacel Pharmaceuticals|CYCC - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Cyclacel

Pambiji fundamental perusahaan:CYCC Cyclacel Pharmaceuticals Inc.

Net asset value per share allows for the elimination of speculative overvaluation by measuring residual capital after all liabilities are settled. For Cyclacel Pharmaceuticals (CYCC), where funding inflows depend on FDA verdicts regarding molecular toxicity, the average book value per share serves as an indicator of financial survival, confirming the biotech's ability to maintain its asset base while ensuring full patient retention in clinical trials.

Pesaing Cyclacel Pharmaceuticals (CYCC)